Review
Open access
Sep 2026
Efficacy and Safety of PD‐1/PD‐L1 Inhibitors Combined With Anti‐Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single‐Arm Meta‐Analysis
To evaluate the efficacy and safety of PD‐1/PD‐L1 inhibitors plus small‐molecule anti‐angiogenic drugs (apatinib, anlotinib and famitinib) for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).
Rong-Yi Hu, Tie-Bin Li, Zi-Man Luo et al.
· Cancer Medicine · 0 citations